{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:49:35Z","timestamp":1775022575332,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013123","name":"Fondation de la recherche en sant\u00e9 du Nouveau-Brunswick","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.exphem.2024.104282","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:15:06Z","timestamp":1721315706000},"page":"104282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["TAZ downregulated ANXA1 expression to modulate myeloma cell interactions with bone marrow mesenchymal stromal cells"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-7605","authenticated-orcid":false,"given":"Samuel O.","family":"Abegunde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-5583","authenticated-orcid":false,"given":"Stacy","family":"Grieve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-8764","authenticated-orcid":false,"given":"Tony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2024.104282_bib0001","series-title":"Cancer: Principles and Practice of Oncology","first-page":"1509","article-title":"Plasma cell neoplasms","author":"Rajkumar","year":"2022"},{"key":"10.1016\/j.exphem.2024.104282_bib0002","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumour microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2024.104282_bib0003","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12943-019-0965-7","article-title":"Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance","volume":"18","author":"Maacha","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2024.104282_bib0004","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.18632\/oncotarget.2058","article-title":"Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease","volume":"5","author":"Garcia-Gomez","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2024.104282_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.leu.2404466","article-title":"Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma","volume":"21","author":"Arnulf","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2024.104282_bib0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.exphem.2009.11.009","article-title":"Distinct Transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease","volume":"38","author":"Todoerti","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2024.104282_bib0007","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/cancers13112542","article-title":"Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression","volume":"13","author":"Maiso","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2024.104282_bib0008","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1186\/1471-2407-14-961","article-title":"Role of intracellular and extracellular annexin A1 in migration and invasion of human pancreatic carcinoma cells","volume":"14","author":"Belvedere","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2024.104282_bib0009","doi-asserted-by":"crossref","first-page":"25074","DOI":"10.18632\/oncotarget.4725","article-title":"Annexin A1 is involved in the acquisition and maintenance of a stem cell-like\/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid","volume":"6","author":"Bizzarro","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.exphem.2024.104282_bib0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/CS20150415","article-title":"Annexin A1 localization and its relevance to cancer","volume":"130","author":"Boudhraa","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.exphem.2024.104282_bib0011","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bbrc.2018.09.140","article-title":"Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo","volume":"505","author":"Jia","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2024.104282_bib0012","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nm.3562","article-title":"Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers","volume":"20","author":"Cottini","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2024.104282_bib0013","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","article-title":"YAP\/TAZ upstream signals and downstream responses","volume":"20","author":"Totaro","year":"2018","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2024.104282_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.06.016","article-title":"Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP\/TEAD activity","author":"Pearson","year":"2021","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.exphem.2024.104282_bib0015","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/bloodadvances.2019000374","article-title":"TAZ functions as a tumour suppressor in multiple myeloma by downregulating MYC","volume":"3","author":"Grieve","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2024.104282_bib0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.exphem.2023.04.004","article-title":"MST1 downregulates TAZ tumor suppressor protein in multiple myeloma and is a potential therapeutic target","volume":"123","author":"Abegunde","year":"2023","journal-title":"Exp Hematol."},{"key":"10.1016\/j.exphem.2024.104282_bib0017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1755-8794-2-18","article-title":"PrognoScan: a new database for meta-analysis of the prognostic value of genes","volume":"2","author":"Mizuno","year":"2009","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.exphem.2024.104282_bib0018","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","article-title":"Genome-wide association between yap\/taz\/tead and ap-1 at enhancers drives oncogenic growth","volume":"17","author":"Zanconato","year":"2015","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2024.104282_bib0019","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.3390\/cancers13164106","article-title":"The association of annexin A1 and chemosensitivity to osimertinib in lung cancer cells","volume":"13","author":"Chuang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2024.104282_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fendo.2020.00017","article-title":"The contribution of chemoattractant GPCRs, formylpeptide receptors, to inflammation and cancer","volume":"11","author":"Liang","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.exphem.2024.104282_bib0021","doi-asserted-by":"crossref","first-page":"17249","DOI":"10.1038\/s41598-020-74350-z","article-title":"Application of small molecule FPR1 antagonists in the treatment of cancers","volume":"10","author":"Ahmet","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.exphem.2024.104282_bib0022","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bbamcr.2018.06.010","article-title":"Inhibition of the AnxA1\/FPR1 autocrine axis reduces MDA-MB-231 breast cancer cell growth and aggressiveness in vitro and in vivo","volume":"1865","author":"Vecchi","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.exphem.2024.104282_bib0023","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-016-2545-1","article-title":"The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis","volume":"16","author":"Snapkov","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2024.104282_bib0024","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1038\/s41598-017-06368-9","article-title":"The expression of formyl peptide receptor 1 is correlated with tumor invasion of human colorectal cancer","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2024.104282_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/1533034618769413","article-title":"Expression and functions of formyl peptide receptor 1 in drug-resistant bladder cancer","volume":"17","author":"Jiang","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.exphem.2024.104282_bib0026","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2024.104282_bib0027","doi-asserted-by":"crossref","first-page":"e67312","DOI":"10.7554\/eLife.67312","article-title":"YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation","volume":"10","author":"He","year":"2021","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.exphem.2024.104282_bib0028","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bbrc.2018.09.140","article-title":"Enhanced antitumour effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo","volume":"505","author":"Jia","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2024.104282_bib0029","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.2022.40.4_suppl.590","article-title":"Efficacy of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer","volume":"40","author":"Dempsey","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2024.104282_bib0030","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1158\/1078-0432.CCR-16-2726","article-title":"Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression","volume":"23","author":"Baglio","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2024.104282_bib0031","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/cancers12051232","article-title":"Communication in the cancer microenvironment as a target for therapeutic interventions","volume":"12","author":"Dominiak","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2024.104282_bib0032","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12935-022-02784-8","article-title":"Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via extracellular vesicles","volume":"22","author":"Naito","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.exphem.2024.104282_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-139811","article-title":"Myeloma derived mitochondrial damage associated molecular patterns promote pro-tumoral expansion by inducing a pro-inflammatory signature in the bone marrow microenvironment","volume":"136","author":"Jibril","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104282_bib0034","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1096\/fj.06-7464rev","article-title":"1: the new face of an old molecule","volume":"21","author":"Lim","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.exphem.2024.104282_bib0035","first-page":"417","article-title":"Annexin A1 in inflammation and breast cancer: a new axis in the tumour microenvironment","volume":"12","author":"Moraes","year":"2018","journal-title":"Cell Adh Migr"},{"key":"10.1016\/j.exphem.2024.104282_bib0036","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.phrs.2017.02.011","article-title":"Annexin A1 influences breast cancer: Controversies on contributions to tumour, host and immunoediting processes","volume":"119","author":"Yan","year":"2017","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.exphem.2024.104282_bib0037","doi-asserted-by":"crossref","first-page":"IJH39","DOI":"10.2217\/ijh-2021-0017","article-title":"Adhesion molecules in multiple myeloma oncogenesis and targeted therapy","volume":"11","author":"Bou Zerdan","year":"2022","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.exphem.2024.104282_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2024.104282_bib0039","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12935-020-01355-z","article-title":"Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis","volume":"20","author":"Peng","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.exphem.2024.104282_bib0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.exphem.2024.104282_bib0041","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/156800912802429337","article-title":"Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma","volume":"12","author":"Neri","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2024.104282_bib0042","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/ph16010070","article-title":"Targeting annexin A1 as a druggable player to enhance the anti-tumor role of honokiol in colon cancer through autophagic pathway","volume":"16","author":"Wang","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.exphem.2024.104282_bib0043","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.7150\/ijms.48244","article-title":"Identification of key genes and pathways in myeloma side population cells by bioinformatics analysis","author":"Yang","year":"2020","journal-title":"Int J Med Sci"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:45:16Z","timestamp":1775015116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X24001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":43,"alternative-id":["S0301472X24001413"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104282","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAZ downregulated ANXA1 expression to modulate myeloma cell interactions with bone marrow mesenchymal stromal cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104282"}}